For Immediate Release Contact firstname.lastname@example.org
April 5, 2011
NEW ORLEANS, April 5, 2011 – Ultrasound is often used as a first-line diagnostic exam to quickly and safely diagnose a range of patient conditions. At this year’s American College of Cardiology (ACC) annual meeting in New Orleans, April 2 – 5, 2011 (Booth # 2847), Toshiba America Medical Systems, Inc., will highlight new enhancements to its cardiac and shared service ultrasound systems that are designed to enhance cardiac ultrasound imaging.
“Toshiba is dedicated to continuously improving its imaging systems to meet the changing needs of healthcare providers,” said Tomohiro Hasegawa, director, Ultrasound Business Unit, Toshiba. “These enhancements to the ultrasound product line build upon Toshiba’s advanced technology to allow quicker, safer and more effective diagnosis, particularly for cardiac exams.”
For its flagship cardiac system, Aplio ArtidaTM, 3D Wall Motion Tracking and Tissue Enhancement technologies are now available. 3D Wall Motion Tracking, an industry first on the Artida, offers a new era of dyssynchrony imaging and advanced regional wall motion assessment. It aids electrophysiologists in optimizing pacemaker placement and function. It also shows 3D ejection fraction, volumes and regional and global strain function. A Toshiba-exclusive software, Tissue Enhancement has the ability to improve image uniformity and endocardial border delineation, especially in difficult-to-scan patients.
Available on Toshiba’s shared service ultrasound systems, AplioTM MX, AplioTM XG and XarioTM XG, the new Auto IMT feature calculates the intima-media thickness of the carotid artery, helping clinicians determine a patient’s risk for cardiovascular disease. Toshiba’s Auto IMT can determine the thickness of the near and far arterial walls from three segments of the carotid artery: at an optimal angle of incidence and two complementary planes. Auto IMT uses the collected images following the American Society of Echocardiography (ASE) consensus statement for diagnosis of cardiac risk in certain asymptomatic populations.
Also at ACC will be Toshiba’s new adult motor-driven TEE probe which improves the diagnosis of numerous cardiac conditions in difficult-to-scan patients.
With headquarters in Tustin, Calif., Toshiba America Medical Systems markets, sells, distributes and services diagnostic imaging systems, and coordinates clinical diagnostic imaging research for all modalities in the United States. Toshiba Medical Systems Corp., an independent group company of Toshiba Corp., is a global leading provider of diagnostic medical imaging systems and comprehensive medical solutions, such as CT, Cath & EP Labs, X-ray, Ultrasound, MRI and information systems. Toshiba Corp. is a worldwide leader in technology, electronic and electrical products, digital consumer products, electronic devices and components, power systems, industrial and social infrastructure systems and home appliances. Toshiba was founded in 1875 and today operates a global network of more than 742 companies with more than 204,000 employees worldwide and annual sales surpassing $68 billion. For more information, visit Toshiba’s website at www.medical.toshiba.com.